Synthelis
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Synthelis - overview
Established
2011
Location
-, -, France
Primary Industry
Biotechnology
About
Synthelis is a French company specializing in innovative biopharmaceutical solutions, focusing on synthetic biology applications to enhance therapeutic protein production and streamline drug development processes. Founded in 2011 in France, Synthelis develops biopharmaceutical solutions. The company has not undergone significant pivots or structural changes since its inception. CEO Bruno Tillier leads the company, which has successfully completed 4 deals to date.
The latest funding round occurred on September 7, 2016, when Synthelis raised EUR 343,350 from investors including Alpes Capital, Casra Capital, Rhone-Alpes Creation, and Viadeo, bringing the total amount raised to EUR 343,350 with a current valuation of EUR 1. 247 mn. Synthelis specializes in the development and provision of innovative biopharmaceutical solutions, primarily focused on synthetic biology applications. The company offers advanced products aimed at enhancing the production and efficiency of therapeutic proteins, integrating technology to optimize biological processes.
Its offerings cater to pharmaceutical companies and research institutions, providing tools that streamline drug development across Europe and North America, targeting sectors that demand precision in biopharmaceutical production. Synthelis generates revenue through B2B partnerships and direct sales of its biopharmaceutical products and services. The company engages in contractual agreements with pharmaceutical firms and research entities, which may include fixed-price contracts for specific projects or ongoing service agreements. Revenue is derived from structured transactions where clients utilize Synthelis's proprietary technologies in their drug development processes, reflecting the value provided through their innovative solutions in the biopharmaceutical sector.
Synthelis aims to enhance its product offerings by designing new biopharmaceutical solutions, though specific product launch dates are not detailed. The company is targeting expansion into additional markets in Europe and North America. The funding raised in September 2016 will support these initiatives, allowing Synthelis to further develop its technologies and enhance its market presence.
Current Investors
Viadeo, Rhone-Alpes Creation, Alpes Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.synthelis.fr
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Synthelis - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.